查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1985612

自動配藥設備市場：按類型、軟體類型、工作流程類型、分銷管道、應用和最終用戶分類－2026年至2032年全球市場預測

Automated Compounding Devices Market by Type, Software Type, Workflow Type, Distribution Channel, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，自動配藥設備市場價值將達到 28.4 億美元，到 2026 年將成長至 31.4 億美元，到 2032 年將達到 58.5 億美元，複合年成長率為 10.89%。

主要市場統計數據
基準年 2025 28.4億美元
預計年份：2026年 31.4億美元
預測年份 2032 58.5億美元
複合年成長率 (%) 10.89%

本文簡要說明了醫療保健產業決策者需要了解的自動配藥系統的作用、營運重點、安全預期和整合考量。

自動化配藥系統在現代無菌配藥流程中扮演著日益重要的角色，其精準性、可重複性和安全性三者相輔相成，共同滿足嚴格的臨床要求。這項技術涵蓋了多種機械結構和軟體層，旨在減少人為操作的差異，提高劑量準確性，並降低污染風險。這些系統在藥房運營、臨床管治和供應鏈管理的交匯點發揮著戰略性作用，並正被廣泛應用於包括急診機構、零售藥房、專科藥房和家庭輸液項目在內的各種場所。

日益複雜的臨床狀況、人才短缺、更嚴格的監管以及軟體主導的整合，正在如何改變藥房配藥的採購重點和營運模式？

自動化配藥領域正經歷一場變革，其驅動力包括日益複雜的臨床情況、勞動力短缺以及監管機構對無菌操作日益成長的關注。先進的治療方法和不斷擴大的生物製藥產品組合要求配藥系統能夠處理日益多樣化的藥物類別，同時保持嚴格的隔離和無菌標準。同時，人手不足以及將訓練有素的藥房人員重新部署到臨床工作的需要，促使人們對自動化配藥產生濃厚的興趣，以減輕人工配藥的負擔，並最大限度地降低高風險任務中的認知負荷。

2025 年關稅調整對醫療設備籌資策略、供應商談判趨勢和生命週期成本考量的影響。

2025年美國實施的關稅政策調整和貿易措施對自動化配藥設備的籌資策略、供應商選擇和總體擁有成本產生了實際的影響。由於部分進口醫療設備和組件的關稅上調，醫療機構和經銷商重新審視了其採購方案。一些機構正在加速轉向國內製造的替代品或區域供應商，以降低關稅風險。這些變化影響了長期服務合約、備件庫存政策和保固條款的談判，因為買家希望保護其營運免受供應鏈中斷和成本上升的影響。

將設備類型、臨床用例、最終用戶環境、通路、軟體模型和工作流程配置與採購邏輯連結起來的綜合細分分析。

一套精細的細分框架揭示了設備選擇和部署優先順序如何因技術類型、臨床應用、使用者環境、分銷管道、軟體架構和工作流程而異。依類型將設備分類時，蠕動式、活塞式和容積式架構各有其獨特的優點。蠕動式設計通常適用於需要封閉系統污染控制的應用；活塞式系統能夠高精度地分配黏稠或可變黏度的製劑；而容積式解決方案則常用於高通量液體處理任務。這些技術差異最終體現為不同治療和操作需求下的適用性差異。

區域趨勢和採用促進因素影響美洲、歐洲、中東和非洲以及亞太地區醫療保健市場的採購選擇、合規期望和服務模式。

區域趨勢對全球範圍內的應用模式、監管重點和供應商策略有顯著影響。在美洲，先進的醫院基礎設施、不斷成長的門診靜脈輸液市場以及腫瘤科和專科藥房等頂級醫療機構的集中，共同推動了市場需求。在這種環境下，符合嚴格的當地監管標準並能與電子健康記錄和條碼檢驗系統無縫整合的解決方案更受青睞。此外，大規模綜合醫療網路通常會尋求與能夠提供集中支援和跨多個站點標準化工作流程的供應商建立合作關係。

競爭優勢包括整合解決方案、檢驗的工作流程、強大的區域服務基礎設施以及滿足臨床和營運需求的創新藍圖。

在自動化配藥領域，競爭優勢越來越依賴提供端到端解決方案的能力，這些解決方案需要結合強大的硬體、可互通的軟體、快速回應的服務網路以及檢驗的工作流程套件。主要企業透過投資於人體工學、危險藥物隔離技術以及強大的互通性框架來脫穎而出，這些框架能夠實現與藥房資訊系統和電子健康記錄的安全資料交換。此外，提供全面的驗證支援、使用者培訓計畫以及可預測的維護服務合約的能力，也能增強部署先進醫療保健系統的買家對供應商的信心。

為領導者提供實用的採購和實施指南，以確保檢驗的系統，增強服務連續性，並透過自動化實現臨床和營運效益。

產業領導者應採取策略性方法，使採購決策與臨床管治目標、營運實際情況和長期服務韌性保持一致。首先，應成立一個跨職能評估委員會，成員包括藥房負責人、感染控制部門、醫療設備工程部門和採購部門，以確保器材選擇能夠體現臨床、安全和技術方面的優先事項。該委員會應制定客觀標準，考慮防護能力、互通性、檢驗支援和本地服務可用性。

結合有針對性的相關人員訪談、監管和標準審查以及供應商檢驗資料的調查方法，確保了可靠和實用的見解。

本執行摘要的研究採用三角測量法，結合了對臨床藥學負責人、醫療設備工程師和分銷合作夥伴的訪談；對無菌配製相關監管指南和標準的二次分析；以及對供應商技術文獻和產品檢驗資料的系統性回顧。主要研究旨在探討從大規模三級醫院到社區藥局等各類機構在運作上所面臨的挑戰、所需功能和服務期望。

將自動化定位為一項需要管治、互通性和持續績效管理的程序化投資，從而應對策略挑戰。

自動化配藥系統已成為現代無菌配藥策略的重要組成部分。在適當的管治和支援下，它們能夠顯著提高準確性、安全性和營運擴充性。系統的架構、軟體功能以及與最終用戶的互動方式決定了自動化能夠帶來多大的臨床和營運價值。因此，採購決策必須基於全面的觀點，綜合考慮技術適用性、法規遵循、供應商服務能力以及員工準備。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：自動配藥設備市場：按類型分類

  • 蠕動
  • 活塞驅動型
  • 正位移

第9章：自動化藥局設備市場：依軟體類型分類

  • 融合的
  • 獨立版

第10章：依工作流程類型分類的自動化配藥設備市場

  • 批次
  • 連續型

第11章：自動配藥設備市場：依通路分類

  • 直銷
  • 銷售代理
    • 全國銷售代理
    • 區域銷售代理
  • 線上銷售

第12章：自動化配藥設備市場：依應用領域分類

  • 緩解疼痛
  • 化療
    • 普通腫瘤科
    • 標靶治療
  • 腸外營養
    • 中央靜脈
    • 周邊靜脈

第13章：自動化藥局設備市場：依最終用戶分類

  • 藥局
  • 家庭醫療保健
  • 醫院藥房
    • 大型醫院
    • 小規模醫院
  • 零售藥房

第14章：自動化藥局設備市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：自動化配藥設備市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：自動化配藥設備市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國自動化藥局設備市場

第18章：中國自動化配藥設備市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Amerisource Bergen Corporation
  • ARxIUM Inc.
  • B. Braun Melsungen AG
  • Baxter Healthcare Corporation
  • Becton, Dickinson and Company
  • Cantel Medical Corp.
  • Capsa Healthcare, Inc.
  • CapsulCN International Co., Ltd.
  • Codonics Inc.
  • Fagron NV
  • ForHealth Technologies
  • Fresenius Kabi AG
  • Fresenius Kabi AG
  • Grifols International SA
  • Health Robotics SRL
  • ICU Medical, Inc.
  • Ivenix, Inc.
  • Loccioni Group
  • McKesson Corporation
  • Meditecno Srl
  • Omnicell, Inc.
  • Qcore Medical, Inc.
  • Quirem Medical BV
  • ScriptPro LLC
  • Swisslog AG
  • Talyst LLC
  • Tecan Group Ltd.
  • Telstar SA
  • Terumo Corporation
Product Code: MRR-BB4648AFF305

The Automated Compounding Devices Market was valued at USD 2.84 billion in 2025 and is projected to grow to USD 3.14 billion in 2026, with a CAGR of 10.89%, reaching USD 5.85 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.84 billion
Estimated Year [2026] USD 3.14 billion
Forecast Year [2032] USD 5.85 billion
CAGR (%) 10.89%

A concise orientation to automated compounding device roles, operational priorities, safety expectations, and integration considerations for healthcare decision-makers

Automated compounding devices are increasingly central to contemporary sterile preparation workflows, where precision, repeatability, and safety converge to meet stringent clinical demands. The technology landscape spans a range of mechanical architectures and software layers designed to reduce manual variability, improve dosing accuracy, and mitigate contamination risks. These systems occupy a strategic role at the intersection of pharmacy operations, clinical governance, and supply chain management, and they are being deployed across acute care settings, retail and specialty compounding pharmacies, and home infusion programs.

As decision-makers consider investments in automated compounding solutions, they are balancing clinical imperatives against operational realities: device integration with existing information systems, compatibility with clinical workflows, staff training needs, and the evolving regulatory scrutiny on aseptic processing. Stakeholders are also observing growing emphasis on traceability and auditability, driven by the need to document chain-of-custody for high-risk preparations. Consequently, procurement evaluation extends beyond the hardware to include software interoperability, vendor support models, and lifecycle maintenance commitments.

In this context, understanding device typologies, application domains, and end-user requirements is essential for framing deployment strategies. Technology choices influence throughput, error rates, and the ability to scale services to meet changing demand patterns. Therefore, an informed introduction to automated compounding must highlight the practical trade-offs between device capabilities, workflow fit, and clinical governance obligations to enable responsible, high-value adoption across care settings.

How clinical complexity, workforce constraints, regulatory rigor, and software-driven integration are reshaping procurement priorities and operational models in compounding

The landscape for automated compounding is undergoing transformative shifts driven by clinical complexity, workforce pressures, and heightened regulatory focus on aseptic processing. Advanced oncology regimens and the widening portfolio of biologics require compounding systems that can handle increasingly diverse drug classes while maintaining stringent containment and sterility profiles. At the same time, labor shortages and the need to reallocate highly trained pharmacy staff toward clinical tasks have accelerated interest in automation that reduces manual preparation burden and minimizes cognitive load during high-risk activities.

Recent technology maturation has emphasized modularity and software-driven orchestration, enabling tighter integration with pharmacy information systems and electronic health records. These developments support improved dose verification, barcode-enabled verification, and electronic batch records that together strengthen quality assurance pathways. Parallel to these technological trends, regulatory authorities are intensifying their expectations for process validation, environmental monitoring, and traceability, prompting providers to prioritize systems with robust audit trails and validated workflows.

Operationally, there is a notable move toward solutions that facilitate decentralized compounding and hybrid service models, where centralized sterile production coexists with point-of-care preparation in outpatient and home settings. This shift is accompanied by renewed attention to supply chain resilience and service continuity, encouraging buyers to evaluate vendor ecosystems for spare parts, local service presence, and software update strategies. Taken together, these factors are reshaping procurement criteria and influencing which device architectures and vendor partnerships are most likely to deliver sustainable clinical and commercial value over time.

Implications of 2025 tariff adjustments on sourcing strategies, vendor negotiation dynamics, and lifecycle cost considerations for device procurement

Tariff policy changes and trade measures enacted in the United States in 2025 have introduced tangible implications for procurement strategies, vendor selection, and total cost of ownership for automated compounding devices. In response to increased duties on certain imported medical devices and components, healthcare organizations and distributors reassessed sourcing options, with some accelerating moves toward domestically manufactured alternatives or regional suppliers to mitigate tariff exposure. These shifts have influenced negotiations around long-term service agreements, spare parts stocking policies, and warranty conditions as buyers sought to insulate operations from supply chain disruptions and cost escalations.

Manufacturers with diversified production footprints or established assembly facilities within tariff-advantaged jurisdictions were relatively better positioned, enabling them to preserve competitive pricing for core devices. Conversely, suppliers reliant on single-country manufacturing faced pressure to absorb higher landed costs or to pass them on to customers, prompting discussions about value-based contracting and extended service commitments to justify revised pricing. For health systems, procurement teams increasingly emphasized total lifecycle assessments, capturing not only acquisition price but also ongoing serviceability, lead times for consumables, and the availability of validated software updates.

Looking ahead, purchasers are incorporating tariff risk into supplier scorecards and contingency planning, evaluating options such as multi-sourcing, local assembly partners, and inventory buffering for critical consumables. These pragmatic responses aim to maintain operational continuity while preserving the clinical benefits of automation. In doing so, organizations are refining procurement policies to balance near-term cost fluctuations against long-term clinical and compliance priorities.

Comprehensive segmentation analysis linking device typologies, clinical use-cases, end-user settings, distribution pathways, software models, and workflow modalities to procurement logic

A nuanced segmentation framework reveals how device selection and deployment priorities vary across technical typologies, clinical applications, user settings, distribution channels, software architectures, and workflow modalities. When categorizing devices by type, peristaltic, piston driven, and volumetric architectures present distinct advantages: peristaltic designs are often favored for closed-system, contamination-controlled modalities; piston driven systems can deliver high-precision dosing for viscous or variable-viscosity formulations; and volumetric solutions are commonly selected for high-throughput liquid handling tasks. These technical differences translate into differential suitability depending on therapeutic and operational needs.

Application-focused segmentation further refines purchasing logic, especially where oncology creates special requirements for containment and hazardous drug handling. Analgesia preparations emphasize dose personalization and rapid turnaround, whereas chemotherapy compounding necessitates secure containment and strict environmental control; within chemotherapy, general oncology regimens and targeted therapies impose divergent requirements for preparation complexity and dose verification. Parenteral nutrition introduces another layer of complexity, where central venous and peripheral venous formulations demand differing volumetric accuracy and compatibility with multi-component mixing protocols.

End-user context shapes operational priorities as well. Compounding pharmacies often prioritize throughput and regulatory documentation; home healthcare services emphasize portability and simplified user interfaces for community nurses; hospital pharmacies need devices that integrate with large electronic ecosystems and accommodate both large hospital and small hospital workflows, each with varying staffing models and physical spaces. Distribution channel dynamics influence access and support models, with direct sales offering close vendor alignment, distributors-whether national or regional-providing reach and aftersales networks, and online sales facilitating transactional procurement for consumables and peripheral software licenses. Software architecture choices between integrated and standalone systems determine how tightly device controls and batch records can be woven into broader pharmacy information systems. Lastly, workflow typologies such as batch and continuous processing define throughput planning and the degree of human oversight required, shaping the physical layout and staffing models around compounding operations. Altogether, this segmentation perspective helps align technical capability with clinical need and operational reality.

Regional dynamics and adoption drivers that shape procurement choices, compliance expectations, and service models across Americas, EMEA, and Asia-Pacific healthcare markets

Regional dynamics exert a material influence on adoption patterns, regulatory priorities, and vendor strategies across the global landscape. In the Americas, demand is shaped by a combination of advanced hospital infrastructure, a growing outpatient infusion market, and concentrated centers of excellence in oncology and specialty pharmacy. This environment favors solutions that demonstrate compliance with rigorous local regulatory standards and that integrate tightly with electronic health records and barcode verification systems. Moreover, large integrated delivery networks often seek vendor partnerships that provide centralized support and standardized workflows across multiple facilities.

In Europe, the Middle East & Africa, regulatory harmonization across certain jurisdictions coexists with notable variations in procurement practices and reimbursement pressures. Providers tend to prioritize clinical safety and environmental controls, while procurement teams evaluate total cost of ownership and service availability across heterogeneous healthcare delivery systems. Regional distributors and localized service organizations play a pivotal role in bridging multinational vendor offerings with local compliance needs and training requirements.

The Asia-Pacific region is characterized by a mix of advanced urban centers with high adoption potential and emerging markets where incremental automation is gaining traction as healthcare capacity expands. In mature urban healthcare systems, integration with hospital information technology and support for high-throughput oncology centers drive demand for robust automation platforms. Meanwhile, in other regional markets, buyers are focused on scalable solutions that balance upfront affordability with modular upgrade paths, enabling phased adoption as clinical volumes and technical capabilities mature. Across all regions, considerations such as local manufacturing, aftersales support footprint, and the availability of regulatory-compliant consumables materially influence vendor competitiveness and adoption velocity.

Competitive differentiators centered on integrated solutions, validated workflows, regional service strength, and innovation roadmaps that address clinical and operational needs

Competitive positioning in the automated compounding space is increasingly influenced by the ability to deliver end-to-end solutions that combine robust hardware with interoperable software, responsive service networks, and validated workflow packages. Leading firms differentiate through investments in human factors engineering, containment technologies for hazardous drugs, and strong interoperability frameworks that enable secure data exchange with pharmacy information systems and electronic health records. In addition, capability to provide comprehensive validation support, user training programs, and predictable maintenance service contracts strengthens vendor credibility with sophisticated health system buyers.

Partnerships between device manufacturers and software integrators are becoming more commonplace, as stakeholders expect seamless batch record generation, barcode verification, and electronic audit trails. Companies that offer modular systems with configurable options for oncology, analgesia, and parenteral nutrition applications are better positioned to address heterogeneous customer needs. Regional service networks and distributor alliances are critical for ensuring timely spare parts delivery and on-the-ground technical support, particularly in markets with complex regulatory or logistical challenges.

Innovation roadmaps that emphasize cloud-enabled analytics, predictive maintenance, and enhanced user interfaces are emerging as differentiators, but they must be balanced against data security and regulatory compliance requirements. Ultimately, providers that demonstrate a commitment to validated workflows, continuous improvement, and transparent post-sale support tend to earn the trust of pharmacy and clinical leaders tasked with safeguarding sterile preparation quality and operational resilience.

Practical procurement and deployment playbook for leaders to secure validated systems, fortify service continuity, and realize clinical and operational gains from automation

Industry leaders should adopt a strategic approach that aligns procurement decisions with clinical governance objectives, operational realities, and long-term service resilience. First, establish a cross-functional evaluation committee that includes pharmacy leadership, infection control, biomedical engineering, and procurement to ensure that device selection reflects clinical, safety, and technical priorities. This committee should define objective criteria that account for containment capabilities, interoperability, validation support, and local service availability.

Second, prioritize vendors who can demonstrate robust integration with existing enterprise systems and who provide validated workflows for the primary clinical applications of interest. Where tariff risk or supply chain fragility exists, consider contractual protections such as price-stability clauses, local assembly options, or predefined parts consignment arrangements to mitigate operational exposure. Additionally, require clear post-sale service-level agreements with measurable response times and defined spare parts availability, so that uptime expectations are aligned with clinical dependency on compounding outputs.

Third, invest in training and change management to ensure effective adoption. Automation gains are realized only when staff are proficient in device operation, troubleshooting, and in reconciling electronic batch records with clinical documentation. Implement phased rollouts-starting with pilot deployments in controlled settings-before scaling across larger hospital or network environments. Finally, embed continuous improvement processes that capture performance metrics, near-miss events, and user feedback to iteratively refine workflows and vendor partnerships. These actions will help leaders transform technology investments into demonstrable improvements in safety, efficiency, and clinical reliability.

Methodological approach combining targeted stakeholder interviews, regulatory and standards review, and vendor validation materials to ensure robust, practice-oriented insights

The research synthesis underpinning this executive summary was developed through a triangulated methodology combining primary interviews with clinical pharmacy leaders, biomedical engineers, and distribution partners; secondary analysis of regulatory guidance and standards relevant to sterile compounding; and a structured review of vendor technical literature and product validation materials. Primary engagements were designed to explore real-world operational challenges, desired feature sets, and service expectations across a spectrum of facility types, from large tertiary hospitals to community-based compounding pharmacies.

Secondary research focused on regulatory frameworks, standard operating procedures for aseptic processing, and best-practice guidance that informs device validation and environmental monitoring. This contextual analysis provided a lens for assessing how product capabilities align with compliance requirements and clinical safety imperatives. Vendor documentation was examined to understand architectural differences between device types, software interoperability options, and service models, with special attention paid to evidence of validated workflows and traceability features.

Synthesis involved iterative validation, where preliminary findings were reviewed with subject-matter experts to ensure accuracy and relevance. The methodology emphasized transparency and reproducibility, documenting assumptions and evidence chains so that stakeholders can assess the provenance of insights. Collectively, this approach supports robust, practice-oriented conclusions while acknowledging the variability in local practice and regulatory interpretation.

Synthesis of strategic imperatives that frame automation as a programmatic investment requiring governance, interoperability, and continuous performance management

Automated compounding devices are now integral to modern sterile preparation strategies, offering pathways to improved precision, enhanced safety, and operational scalability when deployed with appropriate governance and support. The interplay between device architecture, software capabilities, and end-user context determines the degree to which automation delivers clinical and operational value. Consequently, procurement decisions should be informed by a comprehensive view that integrates technical fit, regulatory compliance, vendor serviceability, and workforce readiness.

The current environment presents both opportunities and complexities: advanced therapies and shifting care delivery models increase the clinical need for reliable compounding solutions, while evolving regulatory expectations and supply chain uncertainties demand vigilant procurement and contract design. Organizations that adopt a disciplined, cross-functional approach to evaluation, prioritize interoperability and validated workflows, and secure resilient service arrangements are better positioned to translate automation investments into measurable improvements in safety and efficiency.

In closing, the imperative is clear: treat automation not as an isolated capital purchase but as a strategic program that requires deliberate planning, stakeholder alignment, and continuous performance management. With this posture, healthcare organizations can harness the technical benefits of automated compounding while sustaining the clinical excellence and patient safety that underpin sterile preparation operations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Automated Compounding Devices Market, by Type

  • 8.1. Peristaltic
  • 8.2. Piston Driven
  • 8.3. Volumetric

9. Automated Compounding Devices Market, by Software Type

  • 9.1. Integrated
  • 9.2. Standalone

10. Automated Compounding Devices Market, by Workflow Type

  • 10.1. Batch
  • 10.2. Continuous

11. Automated Compounding Devices Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Distributors
    • 11.2.1. National Distributors
    • 11.2.2. Regional Distributors
  • 11.3. Online Sales

12. Automated Compounding Devices Market, by Application

  • 12.1. Analgesia
  • 12.2. Chemotherapy
    • 12.2.1. General Oncology
    • 12.2.2. Targeted Therapy
  • 12.3. Parenteral Nutrition
    • 12.3.1. Central Venous
    • 12.3.2. Peripheral Venous

13. Automated Compounding Devices Market, by End User

  • 13.1. Compounding Pharmacy
  • 13.2. Home Healthcare
  • 13.3. Hospital Pharmacy
    • 13.3.1. Large Hospital
    • 13.3.2. Small Hospital
  • 13.4. Retail Pharmacy

14. Automated Compounding Devices Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Automated Compounding Devices Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Automated Compounding Devices Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Automated Compounding Devices Market

18. China Automated Compounding Devices Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Amerisource Bergen Corporation
  • 19.6. ARxIUM Inc.
  • 19.7. B. Braun Melsungen AG
  • 19.8. Baxter Healthcare Corporation
  • 19.9. Becton, Dickinson and Company
  • 19.10. Cantel Medical Corp.
  • 19.11. Capsa Healthcare, Inc.
  • 19.12. CapsulCN International Co., Ltd.
  • 19.13. Codonics Inc.
  • 19.14. Fagron N.V.
  • 19.15. ForHealth Technologies
  • 19.16. Fresenius Kabi AG
  • 19.17. Fresenius Kabi AG
  • 19.18. Grifols International S.A.
  • 19.19. Health Robotics SRL
  • 19.20. ICU Medical, Inc.
  • 19.21. Ivenix, Inc.
  • 19.22. Loccioni Group
  • 19.23. McKesson Corporation
  • 19.24. Meditecno S.r.l.
  • 19.25. Omnicell, Inc.
  • 19.26. Qcore Medical, Inc.
  • 19.27. Quirem Medical B.V.
  • 19.28. ScriptPro LLC
  • 19.29. Swisslog AG
  • 19.30. Talyst LLC
  • 19.31. Tecan Group Ltd.
  • 19.32. Telstar S.A.
  • 19.33. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY SOFTWARE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY WORKFLOW TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES AUTOMATED COMPOUNDING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PERISTALTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PERISTALTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PERISTALTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PISTON DRIVEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PISTON DRIVEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PISTON DRIVEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY VOLUMETRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY VOLUMETRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY VOLUMETRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY SOFTWARE TYPE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY INTEGRATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY INTEGRATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY INTEGRATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY STANDALONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY STANDALONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY STANDALONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY WORKFLOW TYPE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY BATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY BATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY BATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY CONTINUOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY CONTINUOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY CONTINUOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY NATIONAL DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY NATIONAL DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY NATIONAL DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY REGIONAL DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY ONLINE SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY ANALGESIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY ANALGESIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY ANALGESIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY GENERAL ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY GENERAL ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY GENERAL ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PARENTERAL NUTRITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PARENTERAL NUTRITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PARENTERAL NUTRITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY CENTRAL VENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY CENTRAL VENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY CENTRAL VENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PERIPHERAL VENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PERIPHERAL VENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PERIPHERAL VENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY COMPOUNDING PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY COMPOUNDING PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY COMPOUNDING PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY LARGE HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY LARGE HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY LARGE HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY SMALL HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY SMALL HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY SMALL HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY SOFTWARE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY WORKFLOW TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY SOFTWARE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY WORKFLOW TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY SOFTWARE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY WORKFLOW TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY SOFTWARE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY WORKFLOW TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY SOFTWARE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY WORKFLOW TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY SOFTWARE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY WORKFLOW TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY SOFTWARE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY WORKFLOW TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY SOFTWARE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY WORKFLOW TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY SOFTWARE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY WORKFLOW TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 188. GCC AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GCC AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. GCC AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY SOFTWARE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. GCC AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY WORKFLOW TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. GCC AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. GCC AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 194. GCC AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. GCC AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. GCC AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 197. GCC AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. GCC AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY SOFTWARE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY WORKFLOW TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY SOFTWARE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY WORKFLOW TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 221. G7 AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. G7 AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. G7 AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY SOFTWARE TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. G7 AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY WORKFLOW TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. G7 AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. G7 AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 227. G7 AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 228. G7 AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 229. G7 AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 230. G7 AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. G7 AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 232. NATO AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. NATO AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. NATO AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY SOFTWARE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. NATO AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY WORKFLOW TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. NATO AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. NATO AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 238. NATO AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. NATO AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 240. NATO AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 241. NATO AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. NATO AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES AUTOMATED COMPOUNDING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY SOFTWARE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY WORKFLOW TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED STATES AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY SOFTWARE TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY WORKFLOW TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY PARENTERAL NUTRITION, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA AUTOMATED COMPOUNDING DEVICES MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)